The OncoSec Medical Inc (ONCS) Announces Earnings Results

The OncoSec Medical Inc (ONCS) Announces  Earnings Results

Shares of OncoSec Medical (NASDAQ:ONCS) opened at 1.14 on Monday. The company has a 50 day moving average of $1.09 and a 200 day moving average of $1.27. The firm’s market cap is $23.79 million. OncoSec Medical has a 1-year low of $0.88 and a 1-year high of $2.08.

OncoSec Medical Inc (NASDAQ:ONCS) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.06, Morningstar.com reports.

Several equities analysts have recently commented on ONCS shares. Noble Financial restated a “buy” rating on shares of OncoSec Medical in a report on Sunday, March 19th. Maxim Group restated a “buy” rating and set a $5.00 price target on shares of OncoSec Medical in a report on Friday, May 12th. HC Wainwright set a $6.00 price target on shares of OncoSec Medical and gave the company a “buy” rating in a report on Monday, May 22nd. Finally, ValuEngine cut shares of OncoSec Medical from a “sell” rating to a “strong sell” rating in a report on Friday. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. OncoSec Medical has a consensus rating of “Buy” and an average target price of $5.67.

An institutional investor recently raised its position in OncoSec Medical stock. Vanguard Group Inc. boosted its position in shares of OncoSec Medical Inc (NASDAQ:ONCS) by 34.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 564,106 shares of the biotechnology company’s stock after buying an additional 144,325 shares during the period. Vanguard Group Inc. owned 2.70% of OncoSec Medical worth $722,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 8.39% of the company’s stock.

OncoSec Medical Company Profile OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:ONCS”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for OncoSec Medical Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for OncoSec Medical Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment